Awaiting development: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 161 to 170 of 294

TitleType
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]Technology appraisal guidance
Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over ID 6475Technology appraisal guidance
Obinutuzumab for treating lupus nephritis ID 6420Technology appraisal guidance
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy TSID 11996Technology appraisal guidance
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]Technology appraisal guidance
Ondansetron for treating alcohol-use disorder TS ID 11884Technology appraisal guidance
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941Technology appraisal guidance
Oral semaglutide for managing overweight and obesity [ID6188]Technology appraisal guidance
Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer ID 6472Technology appraisal guidance
OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]Highly specialised technology

Results per page

  1. 10
  2. 25
  3. 50
  4. All